WF10

DRUG5 trials

Sponsors

Oxo Chemie GmbH, OXO Chemie, Nuvo Research GmbH, Srinakharinwirot University

Conditions

Allergic RhinitisDiabetic Foot Ulcer (DFU)HIV InfectionsUncontrolled Diabetes With Foot Ulcer

Phase 1

A Phase I/II Clinical Study of WF 10 IV Solution ( TCDO ) in Patients With HIV Infection

CompletedNCT00002119

Oxo Chemie GmbHHIV Infections

Updated: 2005-06-24

Phase 2

A Study of WF 10 IV Solution in Patients With Advanced HIV Disease

CompletedNCT00002152

Oxo Chemie GmbHHIV Infections

Target: 60Updated: 2005-06-24

PILOT STUDY OF THE EFFICACY AND SAFETY OF WF10 IN SUBJECTS SUFFERING FROM PERSISTENT ALLERGIC RHINITIS

CompletedNCT01586468

Nuvo Research GmbHAllergic Rhinitis

Start: 2010-03-31End: 2010-11-30Updated: 2012-04-26

Effect of WF10 (TCDO) on HbA1c Values in Diabetic Foot Ulcer Patients

CompletedNCT04372355

Srinakharinwirot UniversityDiabetic Foot Ulcer (DFU), Uncontrolled Diabetes With Foot Ulcer

Start: 2019-06-19End: 2020-06-19Updated: 2020-10-22

Phase 3

A Study to Evaluate the Safety and Effectiveness of WF10 Given to Patients With Late-Stage HIV Disease

CompletedNCT00002244

OXO ChemieHIV Infections

Target: 240Updated: 2005-06-24